Images List Premium Download Classic

Expression Vector

Expression Vector-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Method of manufacturing methoxy-isoflavones by biotransformation and use thereof
Bio-jourdeness International Group Co., Ltd.
July 13, 2017 - N°20170198318

A method of manufacturing methoxy-isoflavones by biotransformation and a use thereof are revealed herein. The method comprises the steps of synthesizing a nucleic acid sequence including a spomt2884 gene ofstreptomyces peucetius; cloning the nucleic acid sequence into an expression vector to form a cyclic recombinant plasmid; transforming the cyclic recombinant plasmid into a microbial expression system (escherichia coli); and incubating ...
Tau protease compositions and methods of use
Oligomerix, Inc.
July 13, 2017 - N°20170198273

Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.
Feline bitter taste receptors and methods
Applied Food Biotechnology, Inc.
July 13, 2017 - N°20170198022

A family of novel feline bitter taste receptors, referred to as feline tas2r (ftas2r), are disclosed herein. Isolated polynucleotides encoding the novel feline bitter taste receptors and chimeric polypeptides are also disclosed, as are expression vectors and host cells for expression of the novel feline bitter taste receptors. Methods of identifying compounds that bind to the novel feline ...
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Polypeptides derived from calcitonin receptors and methods of use
The Research Foundation For The State University New York
July 06, 2017 - N°20170190760

The present invention is based, in part, on our discovery of compositions and methods that can be used to treat a patient who has a compromised bone (due, for example, to a disease such as osteoporosis or an injury such as a bone fracture). The compositions can also be administered prophylactically. For example, they can be administered to help maintain ...
Bsl2v2c2-ig polypeptides
Bristol-myers Squibb Company
July 06, 2017 - N°20170190759

The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3. The present invention further provides isolated b7-related polypeptides, isolated fusion proteins comprising b7-related polypeptides, and ...
Engineered receptors and their use
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
July 06, 2017 - N°20170190758

Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed. The use of these compositions and nanoparticles, such as for the treatment of pain, cystic fibrosis and asthma, is also disclosed.
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Dominant negative mutant krp-related proteins (krp) in zea mays and methods of their use
Targeted Growth, Inc.
June 29, 2017 - N°20170183680

The present invention provides expression vectors comprising polynucleotides encoding mutant zea mays krp dominant negative proteins, and methods of using the same. In addition, transgenic plants expressing said krp dominant negative proteins are provided. Furthermore, methods of increasing average seed weight, seed size, seed number and/or yield of a plant by using said krp dominant negative proteins are provided.
Heterogeneous polypeptide expression cassette
Anaeropharma Science, Inc.
June 29, 2017 - N°20170183667

An object is to provide a signal peptide that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell in a bacterium of the genus bifidobacterium, an expression cassette that can secrete a heterogeneous polypeptide with high efficiency outside the bacterial cell, a heterogeneous polypeptide expression vector, a bacterium of the genus bifidobacterium capable of secreting a heterogeneous ...
Compositions and methods for increasing the expression and signalling of proteins on cell surfaces
The Johns Hopkins University
June 29, 2017 - N°20170183392

The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably ...
Cd40 ligand fusion protein vaccine
Microvax, Llc
June 29, 2017 - N°20170182147

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein. In another approach, an ...
Methods and compositions for suppressing virulence of methicillin resistant staphylococcus aureus
Microvax, Llc
June 29, 2017 - N°20170182145

The present invention is directed to methods of suppressing the virulence of one or more virulence antigenic factors of methicillin resistant staphylococcus aureus (mrsa). Aspects of the invention include administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of a virulence antigenic factor of ...
Well-tolerated and highly specific tailored recombinase for recombining asymmetric target sites in a plurality of ...
Technische Universität Dresden
June 22, 2017 - N°20170175091

The present invention relates to a method for preparing an expression vector encoding a well-tolerated and highly specific tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (ltr) of proviral dna of a plurality of retrovirus strains which may be inserted into the genome of a host cell, as well as to ...
Paramyxovirus virus-like particles as protein delivery vehicles
The Penn State Research Foundation
June 22, 2017 - N°20170175086

Provided are modified virus-like particles (vlps) of paramyxoviruses, compositions containing them, methods of using the vlps for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting vlps, and methods for screening for anti-viral compounds using the vlps. The modified vlps contain a contiguous recombinant polypeptide ...
Expression Vector Patent Pack
Download 166+ patent application PDFs
Expression Vector Patent Applications
Download 166+ Expression Vector-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Expression Vector-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Anti-folate receptor alpha antibodies and uses thereof
Eisai R&d Management Co., Ltd.
June 15, 2017 - N°20170168078

Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, ...
Novel insecticidal proteins from plants
E. I. Du Pont De Nemours And Company
June 15, 2017 - N°20170166921

Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial ...
Secreted proteins
Incyte Corporation
June 15, 2017 - N°20170166888

The invention provides human secreted proteins (secp) and polynucleotides which identify and encode secp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of secp.
Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)
Applied Genetic Technologies Corporation
June 15, 2017 - N°20170166617

This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cdna encoding the rpgr protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (raav) ...
Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
Janssen Vaccines & Prevention B.v.
June 15, 2017 - N°20170165355

Synthetic hiv envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (hiv) infection are described. Viral expression vectors encoding the synthetic hiv envelope proteins can be used in vaccines to provide improved protective immunity against hiv.
Anti-kit antibodies and uses thereof
Celldex Therapeutics, Inc.
June 08, 2017 - N°20170158778

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation. Also ...
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
E.r. Squibb & Sons, L. L. C.
June 08, 2017 - N°20170158767

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to pd-l1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The ...
Ip-10 antibodies and their uses
Bristol-myers Squibb Company
June 08, 2017 - N°20170158757

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to ip-10 with high affinity, inhibit the binding of ip-10 to its receptor, inhibit ip-10-induced calcium flux and inhibit ip-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also ...
Loading